Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma …

High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line
chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study …

Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

Background Mosunetuzumab is a CD20× CD3 T-cell-engaging bispecific monoclonal
antibody that redirects T cells to eliminate malignant B cells. In a phase 1 study …

There is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell
therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord …

Chimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment
paradigms for hematological malignancies, with multi-line therapy-refractory patients …

There is a continuing debate about the proportion of cancer patients that benefit from
precision oncology, attributable in part to conflicting views as to which molecular alterations …

The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly
because of the expanding indications for standard-of-care treatment and the development of …